In this video, health care analyst David Williamson discusses Vertex Pharmaceuticals' recent third-quarter results, breaking down the company's surprising loss and estimate miss, along with the future of its lead drug, Incivek. Watch and find out what investors should take away from these disappointing results.
David Williamson owns shares of Johnson & Johnson. Follow him on Twitter @MotleyDavid. The Motley Fool owns shares of GlaxoSmithKline and Johnson & Johnson. Motley Fool newsletter services recommend GlaxoSmithKline, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
10 Things to Expect From Vertex Pharmaceuticals in 2018
At the J.P. Morgan Healthcare Conference, the biotech's CEO lays out how the company will succeed yet gain this year .
These 4 S&P 500 Stocks Doubled in 2017
Find out which big-cap stocks did the best last year.
3 Great Stocks for Your IRA
These growth, income, and value stocks are ideal for retirement nest eggs.